Health Care

Immutep Limited’s 2026 loss deepens as R&D costs soar, prompting investors to weigh short‑term pain against future breakthrough potential.

Telabio cuts 20% of staff and shuffles leadership to save $17 M annually, aiming to stabilize finances while advancing its soft‑tissue reconstruction tech.

Tilray Brands sees execs buy back shares, boosting confidence in its cannabis growth strategy and global market leadership.

FDA approves Protagonist’s MIMRYLO, the first peptide therapy for polycythemia vera, cutting phlebotomy use and boosting patient energy.

Discover how Biosergen AB is reshaping antifungal therapy with cutting‑edge biopharma research, global reach, and transparent Swedish‑exchange trading.

Gerresheimer AG sees leadership change, Q1 2026 revenue rise 1% yet EBITDA slumps 17 m, amid market volatility and investor scrutiny.

ADVICENNE’s stock slump, negative P/E and 52‑week decline spotlight the firm’s struggle to innovate in pharma—can it reverse fortunes and tackle global health challenges?

Explore why The Cigna Group remains a strong long‑term investment: low P/E, solid fundamentals, and a focused digital‑health, global expansion strategy.

INVO Fertility expands its stock‑incentive plan with 800,000 new shares, boosting employee perks and talent attraction in the fertility treatment sector.

Trulieve, a $2.2B healthcare cannabis firm, blends medical sales with growing political contributions—examining its market challenges and influence.